Sharemaestro company-news research for Biogen Inc. (BIIB34), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
SAO
Brazil
Provisional evidence
Company news sentiment
Latest BIIB34 news and sentiment
Biogen Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score51Neutral is 50
Early balanced news score
19/100 evidence confidence
78% direct company focus
11 current stories across 1 publishers
Current company news
Early balanced news score
11 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone63/100
→
Published 30-day score51/100
Latest source headline
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
finance.yahoo.com · 03 Sep 2026 23:30
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
11 current stories are mapped specifically to BIIB34.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.070.
Confidence is 19/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
78%/100
Company news11 company stories
92/100
Story agreement8/100 difference
News history
Daily score and story count over 30 days
06 Aug21 Aug04 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.07 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness61
recency-weighted evidenceAgreement92
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks10 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
28 Aug 202654BRL 188.289993+0.0%
21 Aug 202658BRL 188.289993+9.5%
14 Aug 202656BRL 172.0+0.0%
07 Aug 202658BRL 172.0+0.0%
31 Jul 202660BRL 172.0+1.0%
24 Jul 202647BRL 170.339996+0.0%
17 Jul 202650BRL 170.339996+0.0%
10 Jul 202650BRL 170.339996-7.5%
Provisional evidence
News subjects
What is shaping the score
Deals and strategy553 stories · 27%
Market update503 stories · 27%
Analyst action832 stories · 18%
Earnings552 stories · 18%
Regulatory and legal501 stories · 9%
Source mix
Where the evidence comes from
finance.yahoo.com558 stories · 73%
TradingKey501 stories · 9%
globenewswire.com501 stories · 9%
Investing.com Canada501 stories · 9%
Recurring subjects
Subjects appearing most often
Biotech8Earnings5Pharma4Clinical Trials3Balance Sheet3Price Target2M A2Immunology2Guidance2Split1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
25 Jun50 neutral04 Sep 13:22
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 04 Sep 13:22 | 52 | +0 | 19/100 (0) | 15 (-1) | Provisional |
| 03 Sep 23:59 | 52 | +0 | 19/100 (-1) | 16 (+2) | Provisional |
| 02 Sep 23:59 | 52 | -2 | 20/100 (-6) | 14 (-3) | Provisional |
| 28 Aug 23:59 | 54 | -1 | 26/100 (+1) | 17 (-9) | Provisional |
| 25 Aug 23:59 | 55 | -3 | 25/100 (-7) | 26 (+1) | Provisional |
| 21 Aug 23:59 | 58 | +2 | 32/100 (+2) | 25 (-1) | Provisional |
| 14 Aug 23:59 | 56 | +1 | 30/100 (+5) | 26 (+1) | Provisional |
| 13 Aug 23:59 | 55 | -1 | 25/100 (-2) | 25 (0) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
finance.yahoo.comDirect company coverageStored article
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Biogen Inc. –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zorevunersen generally well tolerated, with some patients treated for more than 5 years– –Da
BiotechClinical TrialsEpilepsyFda ApprovalNeurodevelopmentPharma
- Published
- 03 Sep 2026 23:30
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.6d old
- Duplicates
- 3 consolidated
#2—Not directional
finance.yahoo.comDirect company coverageStored article
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record. Progress with Alzheimer's treatment LEQEMBI and pipeline assets such as the zorevunersen program for Dra
Balance SheetBiotechEarningsFree Cash FlowFuture Cash FlowsIntrinsic Value
- Published
- 03 Sep 2026 03:25
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.4d old
- Duplicates
- 1 consolidated
#3—Not directional
finance.yahoo.comDirect company coverageStored article
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
On August 6, Biogen (NASDAQ:BIIB) completed its acquisition of RayThera, a privately held biotech developing small-molecule immunology therapies whose lead program entered Phase 1 trials in July 2026. The deal lands just over a week after the company posted a second-quarter beat that sent shares up nearly 5% on July 29. Together, the two moments capture where Biogen stands right now: a company reshaping itself around newer growth engines while still carrying the weight of its aging multiple sclerosis business.Biogen's (BIIB) Immunology Bet Meets A Pricier Balance Sheet A Pipeline Getting Real
BiotechEarningsImmunologyM APharmaSplit
- Published
- 02 Sep 2026 07:48
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.2d old
- Duplicates
- 1 consolidated
#461Tone
finance.yahoo.comDirect company coverageStored article
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 6.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Biogen Inc. before we dive into how investors and analysts have reacted as of late. Q2 Earnings & Sales Beat Biogen reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which signi
AcquisitionBiotechConsensus EstimateEarningsEarnings Per ShareEarnings Release
- Published
- 28 Aug 2026 15:30
- News subject
- Deals and strategy
- Why this score
- Beat expectations
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 69.1% of the score · 6.9d old
- Duplicates
- 1 consolidated
#5—Not directional
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Biogen
Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Biogen "We are honored to provide Vault CRM as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives," said Tom Schwenger, president and CCO at Veeva. "Bringing complex treatments to market requires a highly adaptive commercial strategy, and we are committed to providing the advanced capabilities
BiotechCrmPharma
- Published
- 25 Aug 2026 11:03
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.1d old
- Duplicates
- 1 consolidated
#684Tone
finance.yahoo.comDirect company coverageStored article
Is Biogen (BIIB) Undervalued On Raised EPS Guidance And Key Phase 3 Readouts?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen (BIIB) is back in focus after management raised non GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. See our latest analysis for Biogen. Biogen's recent guidance upgrade comes after a period of renewed momentum, with the share price at US$214.35 and a 30 day share price return of about 8%, while the 1 year total shareholder return of around 54% contrasts with weaker 3 and 5 y
AlzheimersBalance SheetBiotechGuidanceNeurologyPrice Target
- Published
- 21 Aug 2026 17:09
- News subject
- Analyst action
- Why this score
- Guidance raised, Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- High · 59/100
- 30-day weight
- 11.5% of the score · 13.8d old
- Duplicates
- 1 consolidated
#757Tone
finance.yahoo.comDirect company coverageStored article
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders
In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio. This improved outlook, combined with investor attention on five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs, has become a central focus in reassessing the company's long-term profile. Next, we'll examine how Biogen's higher earnings guidance and advancing late-stage pipeline may influence its existing investment narrative. The best AI stocks today may lie beyo
BiotechClinical TrialsEarningsGuidance
- Published
- 21 Aug 2026 13:13
- News subject
- Earnings
- Why this score
- Guidance raised
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 19.5% of the score · 14.0d old
- Duplicates
- 1 consolidated
#8—Not directional
finance.yahoo.comDirect company coverageStored article
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut
Balance SheetClinical TrialsEarningsEarnings GrowthPharmaPrice Target
- Published
- 13 Aug 2026 13:52
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.0d old
- Duplicates
- 1 consolidated
#9—Not directional
TradingKeyDirect company coverageScored from headline
Projeções de Resultados: Biogen Inc (BIIB) — LPA e Crescimento de Receita
- Published
- 07 Aug 2026 09:18
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.2d old
- Duplicates
- 1 consolidated
#10—Not directional
globenewswire.comDirect company coverageStored article
Biogen Completes Acquisition of RayThera Inc.
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program entered Phase 1 development in July 2026. “We are excited about the potential of these immunology assets as we continue to strengthen and dive
BiotechHealthImmunologyM AMergers And AcquisitionsPress Releases
- Published
- 06 Aug 2026 22:15
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.6d old
- Duplicates
- 4 consolidated
#11—Not directional
Investing.com CanadaDirect company coverageScored from headlineSource lookup
Form 144 BIOGEN INC. For: 3 August By Investing.com
- Published
- 06 Aug 2026 10:20
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.1d old
- Duplicates
- 1 consolidated
Earlier company news
BIIB34 news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Sep
01
2026
finance.yahoo.comArchivedNeutral tone
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life– BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protei
BiotechClinical TrialsFda ApprovalPress Releases
- Published
- 1 Sep 2026 12:30
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
finance.yahoo.comArchivedNeutral tone
Biogen Stock: How To Find & Own America's Greatest Opportunities
Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold. Continue Reading
Share Price
- Published
- 5 Aug 2026 13:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
01
2026
finance.yahoo.comArchivedPositive tone
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts' consensus estimates. Is now the time to buy BIIB? Find out in our full research report (it's free). Biogen (BIIB) Q2 CY2026 Highlights: Revenue: $2.74 billion vs analyst estimates of $2.44 billion (3.4% year-on-year growth, 12.1% beat) Adjusted EPS: $3.60 vs analyst estimates of $2.05 (75.8%
BiotechClinical TrialsEarningsFree Cash FlowGuidanceM A
- Published
- 1 Aug 2026 16:47
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Investing.comArchivedLegacy headline · tone unscoredLegacy source lookup
BofA cuts Biogen stock price target on higher expectations bar
- Published
- 31 Jul 2026 10:09
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
finance.yahoo.comArchivedPositive tone
Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?
Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen's profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales performance and earnings. We'll now examine how Biogen's sharp earnings compression, despite year-on-year revenu
BiotechEarningsFda ApprovalNet IncomeNeurologyRevenue Growth
- Published
- 30 Jul 2026 07:08
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
finance.yahoo.comArchivedNeutral tone
Why Biogen Stock Topped the Market Today
One of these enterprises was Biogen (NASDAQ: BIIB), which did quite well in its second quarter. As a reward, investors snapped up the stock, sending it to a nearly 2% gain on the day. This beat the S&P 500 index's 0.2% rise. A biotech in transition Before market open that day, Biogen published those quarterly figures. For the period, the big biotech's revenue was $2.7 billion, 3% higher year over year. The story was quite different on the bottom line, as net income not under generally accepted accounting principles (non-GAAP, or adjusted) slipped to $536 million, or $3.60 per share, from the y
BiotechEarningsEarnings Per ShareGuidanceNet Income
- Published
- 30 Jul 2026 00:43
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
finance.yahoo.comArchivedPositive tone
Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ...
This article first appeared on GuruFocus. Total Revenue: $2.7 billion, up 3% year over year. Core Pharmaceutical Revenue: $1.8 billion, up 4% year over year and 12% quarter over quarter. Growth Portfolio Revenue: Over $1 billion, up 24% year over year and 25% quarter over quarter. SPINRAZA Revenue: $402 million, up 2% year over year and 7% quarter over quarter. VUMERITY Revenue: $197 million, down 7% year over year, up 10% quarter over quarter. LEQEMBI Revenue: $184 million, up 15% year over year and 9% quarter over quarter. SKYCLARYS Revenue: $168 million, up 29% year over year and 11% quarte
AcquisitionClinical TrialsEarningsGuidanceM APharma
- Published
- 29 Jul 2026 22:03
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Jul
29
2026
finance.yahoo.comArchivedNeutral tone
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Biogen Inc. (BIIB) reported $2.74 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 3.4%. EPS of $3.60 for the same period compares to $5.47 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.5 billion, representing a surprise of +9.4%. The company delivered an EPS surprise of +18.42%, with the consensus EPS estimate being $3.04. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accura
BiotechEarnings
- Published
- 29 Jul 2026 15:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
finance.yahoo.comArchivedPositive tone
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026 Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts' consensus estimates. Is now the time to buy Biogen? Find out in our full research report. Biogen (BIIB) Q2 CY2026 Highlights: Revenue: $2.74 billion vs analyst estimates of $2.44 billion (3.4% year-on-year growth, 12.1% beat) Adjusted EPS: $3.60 vs analyst estimates of $2.05 (75.8% beat) Management raised its full-year Adjusted EPS guidance to $16
BiotechEarningsEarnings Per ShareGuidanceRevenue Growth
- Published
- 29 Jul 2026 13:15
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
finance.yahoo.comArchivedPositive tone
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +18.42%. A quarter ago, it was expected that this company would post earnings of $2.95 per share when it actually produced earnings of $3.57, delivering a surprise of +21.02%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Biogen, which belongs to the Zacks Medi
BiotechEarningsEarnings EstimateEarnings ReleaseEarnings ReportEarnings Surprise
- Published
- 29 Jul 2026 12:30
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
finance.yahoo.comArchivedPositive tone
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales
Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts' estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer's drug Leqembi narrowly missed expectations. Revenue rose 3% to $2.74 billion, above the $2.47 billion Bloomberg consensus, while product revenue increased 2% to $1.92 billion, topping expectations of $1.77 billion. Adjusted earnings per share fell to $3.60 from $5.47 a year earlier but exceeded the $2.89 consensus. Biogen said Growth Portfolio revenu
BiotechEarningsEarnings Per ShareGuidance
- Published
- 29 Jul 2026 11:45
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
seekingalpha.comArchivedPositive tone
Biogen beats top-line and bottom-line estimates; updates FY26 outlook
* Biogen press release [https://seekingalpha.com/filing/309872127] (BIIB [https://seekingalpha.com/symbol/BIIB]): Q2 Non-GAAP EPS of $3.60 beats by $1.57. * Revenue of $2.7B (+3.8% Y/Y) beats by $240M. * SPINRAZA revenue of $402 million, up 2% year-over-year. * VUMERITY second quarter revenue of $197 million, down 7% year-over-year, primarily impacted by inventory dynamics; first half growth of 7% year-over-year. * Full Year 2026 Financial Guidance Biogen is updating its full year 2026 financial guidance to reflect a strengthening in underlying business performance outlook with reported guidan
EarningsEarnings NewsGuidancePharmaRevenue GrowthTotal Revenue
- Published
- 29 Jul 2026 11:20
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
29
2026
finance.yahoo.comArchivedPositive tone
Biogen beats quarterly estimates as newer drugs fuel growth
July 29 (Reuters) - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand for its rare-disease medicines, while sales of its legacy multiple sclerosis drugs stayed under pressure. Investors are closely watching whether recent deals and newer products including its Alzheimer's drug Leqembi can reignite growth and help the company navigate mounting competition and pricing pressure across its aging multiple sclerosis portfolio. Despite an upbeat quarter, Biogen cut its 2026 adjusted per-share profit forecast to between $12 an
BiotechEarningsM APharma
- Published
- 29 Jul 2026 11:03
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
finance.yahoo.comArchivedNeutral tone
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here's what to look for. Biogen beat analysts' revenue expectations last quarter, reporting revenues of $2.48 billion, up 1.9% year on year. It was a strong quarter for the company, with a beat of analysts' EPS estimates. Is Biogen a buy or sell going into earnings? Read our full analysis here, it's free for active Edge members. This quarter, the market is expecting Biogen's revenue to decline 7.8% year on year, a reversal fr
BiotechEarnings
- Published
- 28 Jul 2026 14:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
Market sourceArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen Inc. (BIIB) stock price, news, quote and history
- Published
- 28 Jul 2026 06:09
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
finance.yahoo.comArchivedNegative tone
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussi
BiotechConsensus EstimateEarningsEarnings ReleaseEarnings ReportEstimate Revisions
- Published
- 22 Jul 2026 15:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
GuruFocusArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors
- Published
- 22 Jul 2026 11:39
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
13
2026
GuruFocusArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen Inc (MEX:BIIB) Stock Price, Trades & News
- Published
- 13 Jul 2026 17:04
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
GuruFocusArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen Inc (BIIB) Shares Fall 3.5% -- GF Value Says Still Overva
- Published
- 7 Jul 2026 06:19
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
GuruFocusArchivedLegacy headline · tone unscoredLegacy source lookup
Is Biogen Inc (BIIB) Overvalued After 3.0% Rally? GF Value Says
- Published
- 3 Jul 2026 18:08
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
GuruFocusArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen Inc (BIIB) Shares Surge 7.0% -- What GF Score of 74 Tells Investors
- Published
- 2 Jul 2026 11:49
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
Ad-hoc-news.deArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen marks a fresh 52-week high, shares extend NASDAQ biotech rally
- Published
- 26 Jun 2026 08:58
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
Investing.comArchivedLegacy headline · tone unscoredLegacy source lookup
Biogen stock reaches 52-week high at 206.21 USD
- Published
- 26 Jun 2026 00:29
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Oct
30
2025
ADVFNArchivedNeutral tone
Ações da Biogen caem após reduzir previsão de lucros para o ano todo
- Published
- 30 Oct 2025 07:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Apr
28
2021
Investidor10ArchivedNeutral tone
BDR Biogen - BIIB34 - Resultados, Dividendos, Cotação e Indicadores
- Published
- 28 Apr 2021 16:19
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Apr
03
2021
Investidor10ArchivedNeutral tone
Stock Biogen - Stock BIIB - Resultados, Dividendos, Cotação e Indicadores
- Published
- 3 Apr 2021 11:22
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to BIIB34, but the headline and available text are not mainly about Biogen Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of BIIB34 sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.